Please login to the form below

Not currently logged in
Email:
Password:

opioid addiction

This page shows the latest opioid addiction news and features for those working in and with pharma, biotech and healthcare.

FDA awards another non-opioid pain drug breakthrough status

FDA awards another non-opioid pain drug breakthrough status

Second drug fast-tracked amid addiction epidemic. The FDA is prioritising the approval of new non-opioid pain treatments, as part of the US battle against its opioid addiction epidemic. ... prevent more people becoming addicted to opioid painkillers

Latest news

  • Regeneron and Teva close gap on rivals with NGF pain drug Regeneron and Teva close gap on rivals with NGF pain drug

    Nevertheless, fasinumab and tanezumab are now leading what analysts consider could be a highly-lucrative market for drugs that deliver effective pain relief without the risk of side effects and addiction ... In contrast to opioids, which alter pain

  • Indivior push to diversify boosted by schizophrenia drug approval Indivior push to diversify boosted by schizophrenia drug approval

    For years, Indivior has made the bulk of its revenues from opioid addiction treatment Suboxone. ... Perseris is a key product in Indivior’s diversification plans, along with newer painkiller addiction therapy Sublocade (long-acting buprenorphine) which

  • The year of the blockbuster The year of the blockbuster

    The diseases targeted by the report’s projected market entrants include type 2 diabetes, endometriosis, childhood epilepsy, haemophilia, HIV, migraine, opioid addiction and shingles. ... Sublocade (buprenorphine) from Indivior:Sublocade, having been

  • Heron boosted by new data for ‘breakthrough’ pain drug Heron boosted by new data for ‘breakthrough’ pain drug

    opioid analgesics compared to both placebo and local anaesthesia monotherapy with bupivacaine in the first 48 hours after surgery. ... The reduction in opioid use is another important facet of the new therapy, given the US’s current epidemic of opioid

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    The US regulator issued a ‘refusal to file’ letter to the company yesterday for the drug, which is a fixed-dose combination of buprenorphine, an opioid used for many years to ... treat addiction, and samidorphan, a new mu-opioid receptor antagonist.

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • IOTOD: Improving Opioid Dependence Outcomes

    IOTOD’s future. The IOTOD educational initiative perpetually aims to provide the most up-to-date information in the field of opioid addiction. ... in opioid addiction and gain valuable insight on some of the most controversial topics in the field.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics